Literature DB >> 9465096

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

A Nagy1, A V Schally, G Halmos, P Armatis, R Z Cai, V Csernus, M Kovács, M Koppán, K Szepesházi, Z Kahán.   

Abstract

To create cytotoxic hybrid analogs of somatostatin (SST), octapeptides RC-160 (D-Phe-Cys-Tyr-D-Trp- Lys-Val-Cys-Trp-NH2) and RC-121 (D-Phe-Cys-Tyr-D-Trp- Lys-Val-Cys-Thr-NH2) were linked to doxorubicin (DOX) or its superactive derivative, 2-pyrrolino-DOX (AN-201). The conjugation was performed by coupling N-9-fluorenylmethoxycarbonyl (N-Fmoc)-DOX-14-O-hemiglutarate or 2-pyrrolino-DOX-14-O-hemiglutarate to the amino terminus of [Lys(Fmoc)5]RC-160 yielding AN-163 and AN-258, respectively, after deprotection. The respective cytotoxic conjugates of RC-121 (AN-162 and AN-238) were prepared similarly. In vitro tests on human cancer cell lines-MKN-45 gastric cancer, MDA-MB-231 breast cancer, PC-3 prostate cancer, and MIA PaCa-2 pancreatic cancer-demonstrated that the antiproliferative activity of the cytotoxic radicals in these conjugates was virtually retained. In H-345 human small cell lung carcinoma cell line, conjugates of RC-121 preserved the cytotoxic activity of their radicals, but the hybrids with RC-160 showed approximately 10 times lower activity. The ability of the carriers and the hybrids to inhibit the binding of 125I-labeled RC-160 to receptors for SST on rat pituitary membrane preparation was also determined. The cytotoxic conjugates inhibited 50% of the specific binding of the radioligand in the nanomolar concentration range (IC50 < 80 nM). When SST-like activities of AN-238 and its carrier, RC-121, were compared in the rat pituitary superfusion system, both compounds were found to suppress a stimulated growth hormone release at nanomolar concentrations. Preliminary studies in animal models of breast and prostate cancers showed that AN-238 is less toxic than AN-201 and more potent in inhibiting tumor growth. These highly active cytotoxic analogs of SST have been designed as targeted antitumor agents for the treatment of various cancers expressing receptors for SST octapeptides.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9465096      PMCID: PMC19192          DOI: 10.1073/pnas.95.4.1794

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

Authors:  A Nagy; P Armatis; R Z Cai; K Szepeshazi; G Halmos; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

2.  Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.

Authors:  J A Plumb; R Milroy; S B Kaye
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

3.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

Review 4.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

5.  Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.

Authors:  M Miyazaki; A Nagy; A V Schally; N Lamharzi; G Halmos; K Szepeshazi; K Groot; P Armatis
Journal:  J Natl Cancer Inst       Date:  1997-12-03       Impact factor: 13.506

Review 6.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

7.  A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.

Authors:  W A Breeman; L J Hofland; M van der Pluijm; P M van Koetsveld; M de Jong; B Setyono-Han; W H Bakker; D J Kwekkeboom; T J Visser; S W Lamberts
Journal:  Eur J Nucl Med       Date:  1994-04

Review 8.  Somatostatin analogs for diagnosis and treatment of cancer.

Authors:  G Weckbecker; F Raulf; B Stolz; C Bruns
Journal:  Pharmacol Ther       Date:  1993-11       Impact factor: 12.310

9.  Somatostatin receptor subtype gene expression in human and rodent tumors.

Authors:  P A Eden; J E Taylor
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

10.  Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

Authors:  L Buscail; N Delesque; J P Estève; N Saint-Laurent; H Prats; P Clerc; P Robberecht; G I Bell; C Liebow; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  20 in total

1.  Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release.

Authors:  Shuyi Chen; Xianrui Zhao; Jingyi Chen; Jin Chen; Larisa Kuznetsova; Stanislaus S Wong; Iwao Ojima
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

2.  Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

Authors:  A Nagy; A Plonowski; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.

Authors:  M Gugger; J C Reubi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

4.  Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.

Authors:  Stefan Buchholz; Gunhild Keller; Andrew V Schally; Gabor Halmos; Florian Hohla; Elmar Heinrich; Frank Koester; Benjamin Baker; Jörg B Engel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

5.  Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

Authors:  N Benali; P Cordelier; D Calise; P Pages; P Rochaix; A Nagy; J P Esteve; P M Pour; A V Schally; N Vaysse; C Susini; L Buscail
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

6.  Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.

Authors:  Sumit Majumdar; Bimo A Tejo; Ahmed H Badawi; David Moore; Jeffrey P Krise; Teruna J Siahaan
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

7.  Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.

Authors:  K Maruno; A Absood; S I Said
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

8.  Supramolecular filaments containing a fixed 41% paclitaxel loading.

Authors:  Ran Lin; Andrew G Cheetham; Pengcheng Zhang; Yi-an Lin; Honggang Cui
Journal:  Chem Commun (Camb)       Date:  2013-05-28       Impact factor: 6.222

9.  Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.

Authors:  C G Ziegler; J W Brown; A V Schally; A Erler; L Gebauer; A Treszl; L Young; L M Fishman; J B Engel; H S Willenberg; S Petersenn; G Eisenhofer; M Ehrhart-Bornstein; S R Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-27       Impact factor: 11.205

Review 10.  Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.

Authors:  Florian Hohla; Thomas Winder; Richard Greil; Ferenc G Rick; Norman L Block; Andrew V Schally
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.